Literature DB >> 26330164

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Hillary G Caruso1, Lenka V Hurton1, Amer Najjar2, David Rushworth1, Sonny Ang2, Simon Olivares2, Tiejuan Mi2, Kirsten Switzer2, Harjeet Singh2, Helen Huls2, Dean A Lee1, Amy B Heimberger3, Richard E Champlin4, Laurence J N Cooper5.   

Abstract

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors (CAR) due to potential for deleterious recognition of normal cells. We sought to generate CAR(+) T cells capable of distinguishing malignant from normal cells based on the disparate density of EGFR expression by generating two CARs from monoclonal antibodies that differ in affinity. T cells with low-affinity nimotuzumab-CAR selectively targeted cells overexpressing EGFR, but exhibited diminished effector function as the density of EGFR decreased. In contrast, the activation of T cells bearing high-affinity cetuximab-CAR was not affected by the density of EGFR. In summary, we describe the generation of CARs able to tune T-cell activity to the level of EGFR expression in which a CAR with reduced affinity enabled T cells to distinguish malignant from nonmalignant cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26330164      PMCID: PMC4624228          DOI: 10.1158/0008-5472.CAN-15-0139

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Strength of prior stimuli determines the magnitude of secondary responsiveness in CD8+ T cells.

Authors:  Dong-Gyun Lim; Per Höllsberg; David A Hafler
Journal:  Cell Immunol       Date:  2002 May-Jun       Impact factor: 4.868

2.  Insulin and epidermal growth factor. Human fibroblast receptors related to deoxyribonucleic acid synthesis and amino acid uptake.

Authors:  M D Hollenberg; P Cuatrecasas
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

3.  Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.

Authors:  David M Barrett; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

4.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

5.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

6.  Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Authors:  Sharyn Thomas; Shao-An Xue; Charles R M Bangham; Bent K Jakobsen; Emma C Morris; Hans J Stauss
Journal:  Blood       Date:  2011-05-23       Impact factor: 22.113

7.  Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Authors:  Claire N Janicki; S Rhiannon Jenkinson; Neil A Williams; David J Morgan
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 8.  T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity.

Authors:  Jennifer D Stone; Adam S Chervin; David M Kranz
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

9.  Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses.

Authors:  A S Chervin; J D Stone; C M Soto; B Engels; H Schreiber; E J Roy; D M Kranz
Journal:  Gene Ther       Date:  2012-10-11       Impact factor: 5.250

10.  Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines.

Authors:  Paolo Romano; Assunta Manniello; Ottavia Aresu; Massimiliano Armento; Michela Cesaro; Barbara Parodi
Journal:  Nucleic Acids Res       Date:  2008-10-15       Impact factor: 16.971

View more
  162 in total

Review 1.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

Review 2.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

3.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

Review 4.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 5.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

6.  Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Thomas J Perry; Lakmal Rozumalski; Benjamin J Hackel; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2018-12-17       Impact factor: 15.419

Review 7.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 8.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

9.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.